Treatment Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

What are the long-term effects of stem cell transplant on survival of patients with unresponsive Hodgkin’s lymphoma?

Posted by on Jun 14, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of stem cell transplantation (SCT) on survival in patients with unresponsive Hodgkin’s lymphoma (HL). This study found that SCT was safe and effective in patients with HL that is unrepsonsive to treatment. Some background Hodgkin's Lymphoma is a type of cancer of...

Read More

Is pembrolizumab better than the standard of care in unresponsive Hodgkin’s Lymphoma?

Posted by on Jun 11, 2018 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated if pembrolizumab (Keytruda) was more effective than the standard of care in Hodgkin's lymphoma patients unresponsive to brentuximab vedotin (Adcetris). The main finding was that pembrolizumab was more effective than the standard of care in these patients Some background Hodgkin's Lymphoma is...

Read More

Treatment of Mixed-type urinary incontinence in women, with propiverine hydrochloride

Posted by on Jun 11, 2018 in Urinary incontinence | 0 comments

In a nutshell This study looked at Propiverine Hydrochloride (PH – Aponorm) in the treatment of stress urinary incontinence in women with mixed type urinary incontinence. It concluded that PH reduced cases of incontinence in both stress and urge urinary incontinence. Some background Mixed urinary incontinence is a mix of stress (SUI –...

Read More

Carfilzomib – once weekly or twice weekly to treat unresponsive multiple myeloma?

Posted by on Jun 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...

Read More

MOR208: a new antibody therapy for relapsed or refractory non-Hodgkin’s lymphoma

Posted by on Jun 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of MOR208 in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma. This study concluded that MOR208 monotherapy was safe and showed promising results in these patients. Some background Chemoimmunotherapy is the current standard first-line...

Read More

Long-term outcomes of ibrutinib plus rituximab for relapsed or refractory mantle cell lymphoma

Posted by on Jun 9, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the long-term safety and effectiveness of ibrutinib (Imbruvica) plus rituximab (Rituxan) for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that this treatment is safe and effective for relapsed or refractory mantle cell lymphoma. Some background Mantle cell...

Read More

Is dasatinib effective with chemotherapy in the treatment of Philadelphia-chromosome postitive ALL?

Posted by on Jun 9, 2018 in Leukemia | 0 comments

In a nutshell This study examined the effect of dasatinib (Sprycel) in addition to intensive chemotherapy in the treatment of children and young adults with acute lymphoblastic leukemia (ALL). The study concluded that dasatinib with chemotherapy was a safe and effective way to treat ALL. Some background Acute lymphoblastic leukemia (ALL) is a...

Read More